43 results on '"Bressler, B"'
Search Results
2. P477 Performance of bowel preparation quality scales in patients with Crohn’s disease
3. DOP46 Tofacitinib for hospitalized acute severe Ulcerative Colitis – the TRIUMPH study
4. DOP49 Guselkumab improves health-related quality of life as measured by PROMIS-29 in patients with moderately to severely active Ulcerative Colitis: Phase 3 QUASAR induction study
5. P789 Impact of risk factors for Janus kinase inhibitor use identified by the Pharmacovigilance Risk Assessment Committee on the safety and efficacy of ozanimod in patients with moderately to severely active ulcerative colitis
6. P627 Real-world clinical effectiveness and safety of vedolizumab and ustekinumab in biologic-naïve patients with Crohn’s disease by disease location: Results from the EVOLVE Expansion study
7. P1010 Guselkumab improves abdominal pain and bowel urgency symptoms in patients with moderately to severely active ulcerative colitis: Results from the phase 3 QUASAR induction study
8. P954 Cumulative response to guselkumab through week 24 of induction in patients with moderately to severely active ulcerative colitis: Results from the phase 3 QUASAR induction study
9. P584 Efficacy, safety, and tolerability of AMT-101, a gut selective oral IL-10 fusion, in the Phase 2 FILLMORE trial of patients with chronic pouchitis
10. P777 Deployment of an artificial intelligence tool for precision medicine in ulcerative colitis: Preliminary data from 8 globally distributed clinical sites
11. OP08 Mucosal healing with vedolizumab in inflammatory bowel disease patients with chronic pouchitis: Evidence from EARNEST, a randomized, double-blind, placebo-controlled trial
12. P752 Predictors of time to relapse upon ozanimod withdrawal in patients with moderately to severely active ulcerative colitis
13. P268 Development and validation of a novel composite index for the assessment of endoscopic and histologic disease activity in pouchitis: The Atlantic pouchitis index
14. P585 Duration of response to ozanimod after treatment withdrawal: results from the phase 3 True North study
15. P636 Real-world clinical effectiveness and safety of vedolizumab and ustekinumab in biologic-naïve patients with Crohn’s disease: Results from the EVOLVE Expansion study
16. P019 Host-Enterobacteriaceae interactions and mitochondrial dysfunction in Crohn’s colitis
17. OP04 Vedolizumab intravenous is effective across multiple treatment targets in chronic pouchitis: Results of the randomised, double-blind, placebo-controlled EARNEST trial
18. OP23 The efficacy and safety of guselkumab induction therapy in patients with moderately to severely active Ulcerative Colitis: Phase 2b QUASAR Study results through week 12
19. DOP60 Simplified rules to identify bio-naïve patients with Crohn’s Disease with higher likelihood of clinical remission when initiating vedolizumab versus anti-TNFα therapies: Analysis of EVOLVE study data
20. OP31 RESTORE: Interim analysis of a Phase 2 study of QBECO SSI for the induction and maintenance of clinical and endoscopic remission in subjects with Moderate to Severe Crohn’s Disease
21. P119 There is minimal agreement on the recognition of deep ulcers as seen on endoscopy in patients with Inflammatory Bowel Disease: a national survey
22. P393 Patient and physician perspectives on the management of inflammatory bowel disease: Role of steroids in the context of biologic therapy
23. P511 Association of ustekinumab serum concentrations and clinical outcomes: results from the mUST-DECIDE trial
24. P419 Clinical effectiveness and safety of first-line biologic vedolizumab as a monotherapy or combination therapy in ulcerative colitis and Crohn’s disease patients: results from the EVOLVE study
25. P539 Assessment of age as a risk factor for adverse events in patients from the tofacitinib ulcerative colitis clinical programme
26. P482 Patient and physician perspectives on the management of inflammatory bowel disease: Disease remission and durability of treatment
27. DOP55 A real-world comparison of the effectiveness and safety of vedolizumab and anti-TNF therapies in early treatment initiation with first-line biologic therapy in ulcerative colitis: Results from EVOLVE
28. P387 Real-world clinical outcomes of biologic-naïve non-complicated Crohn’s disease patients treated with vedolizumab: Results from the EVOLVE study
29. DOP15 Transmural healing with vedolizumab in patients with active Crohn’s disease
30. P233 Do you see what I see? Teaching Gastroenterology trainees how to report endoscopic findings
31. P621 Real-world effectiveness and safety of vedolizumab and anti-TNF in biologic-naive Crohn’s disease patients: results from the EVOLVE study
32. P561 Impact of ustekinumab TDM on clinical practice: a multi-centre, prospective, cross-sectional observational trial—mUST-Decide
33. P685 Improvement in patient-reported Inflammatory Bowel Disease Questionnaire outcomes, and relationship with disease activity, in tofacitinib-treated patients with ulcerative colitis: Data from the OCTAVE clinical trials
34. P573 Real-world effectiveness and safety of vedolizumab and anti-TNF in biologic-naive ulcerative colitis patients: Results from the EVOLVE study
35. P546 Vedolizumab outcomes in real-world bio-naive ulcerative colitis and Crohn’s disease patients (EVOLVE) in Canada: Interim results
36. P188 Do you see what I see? An assessment of recognition and description of endoscopic inflammation by gastroenterology trainees and staff physicians
37. P134 Home based faecal calprotectin testing: a Canadian user performance evaluation study of IBDoc®
38. P516 Efficacy and safety of tofacitinib retreatment for ulcerative colitis after treatment interruption: Results from the OCTAVE clinical trials
39. P597 Ustekinumab use in Crohn's disease: a tertiary centre experience
40. P625 Ustekinumab use in Crohn's disease: effectiveness of dose escalation
41. P151 Recommendations for creating a high quality endoscopy report for inflammatory bowel disease patients: results from a RAND-appropriateness panel
42. OP004 Early combined immunosuppression for the management of Crohn's disease: A community-based cluster randomized trial
43. P509 Evaluating clinical practice patterns with inflammatory bowel disease health care assessment questionnaires (POLARIS): a patient- and a physician-reported survey
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.